Since the increased protein levels of EZH2 predict early recurrence and tumor progression in recurrence (Figure 2B; see also [7]), we sought to determine whether miR-101 and/or miR-138 could also be predictive biomarkers of clinical outcome in NMIBC. Here, EZH2 is linked to neoplasm.